Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ALS LIMITED Board/Management Information 2024

Oct 21, 2024

64365_rns_2024-10-21_28e4e202-cb04-40a6-af92-ecfe72bbe002.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

asx release

==> picture [51 x 55] intentionally omitted <==

22 October 2024

ALS announces departure of Andreas Jonsson, EGM Food & Pharmaceutical

ALS Limited (ASX: ALQ) advises that Andreas Jonsson, Executive General Manager Food & Pharmaceutical, will be departing the business on 31 March 2025. During the coming months, he will support the transition and transformation plans for Nuvisan. The process to appoint his successor has commenced.

CEO and Managing Director, Malcolm Deane, said: “The Board and I would like to thank Andreas for his leadership and significant contribution to ALS over the past 19 years and wish him every success in the future.

ENDS

Authorised for release by the Company Secretary.

For further information please contact:

For further information please contact:
Michael Williams Investor Relations
Group Treasurer, Investor Relations & Business Integration Director [email protected]
[email protected] ALS Limited
M: + 61 409 001 308

About ALS Limited (ASX: ALQ)

ALS is a global leader in testing, providing comprehensive testing solutions to clients in a wide range of industries around the world. Using state-of-the-art technologies and innovative methodologies, our dedicated international teams deliver the highest-quality testing services and personalised solutions supported by local expertise. We help our clients leverage the power of data-driven insights for a safer and healthier world.

alsglobal.com

1